Evoke Pharma Inc (EVOK) concluded trading on Wednesday at a closing price of $6.99, with 139.78 million shares of worth about $977.04 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 50.65% during that period and on July 09, 2025 the price saw a gain of about 162.78%. Currently the company’s common shares owned by public are about 1.49M shares, out of which, 1.41M shares are available for trading.
Stock saw a price change of 162.78% in past 5 days and over the past one month there was a price change of 136.95%. Year-to-date (YTD), EVOK shares are showing a performance of 7.87% which increased to 58.14% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.94 but also hit the highest price of $12.32 during that period. The average intraday trading volume for Evoke Pharma Inc shares is 15.70K. The stock is currently trading 136.06% above its 20-day simple moving average (SMA20), while that difference is up 122.61% for SMA50 and it goes to 72.39% higher than SMA200.
Evoke Pharma Inc (NASDAQ: EVOK) currently have 1.49M outstanding shares and institutions hold larger chunk of about 16.22% of that.
The stock has a current market capitalization of $10.44M and its 3Y-monthly beta is at -0.08. It has posted earnings per share of -$3.18 in the same period. It has Quick Ratio of 1.50 while making debt-to-equity ratio of 0.88. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for EVOK, volatility over the week remained 17.31% while standing at 10.60% over the month.
Stock’s fiscal year EPS is expected to rise by 64.06% while it is estimated to increase by 247.52% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on June 22, 2020 offering a Buy rating for the stock and assigned a target price of $10 to it. On March 08, 2018, B. Riley FBR Inc. Reiterated their recommendations, while on October 19, 2017, FBR & Co. Resumed their ratings for the stock with a price target of $10. Stock get a Buy rating from Rodman & Renshaw on March 16, 2017.
